Original Article

Invasive Group A Streptococcal Infections in Florida

Authors: Zuber D. Mulla, PHD, MSPH, Paul E. Leaverton, PHD, Steven T. Wiersma, MD, MPH

Abstract

Background Several previous studies of invasive Group A streptococcal (GAS) disease have been hindered by small sample sizes (≤ 100 patients) and limited generalizability. Methods We conducted a population-based study of invasive GAS disease. The objectives of the study were to describe the clinical features of individuals who were hospitalized for invasive GAS disease and to identify risk factors for hospital mortality. The cases were 257 patients who were hospitalized throughout Florida during a 4-year period and reported to the Florida Department of Health. Logistic regression was used to calculate adjusted odds ratios (OR) for mortality and 95% confidence intervals (CI). Results The overall mortality was 18% (41 of 228). Admission into an intensive care unit was a strong predictor of mortality (OR, 20.41; 95% CI, 6.41–64.96). Treatment with clindamycin reduced mortality in patients who had necrotizing fasciitis (OR, 0.11; 95% CI, 0.01–0.89) but not in patients who did not have necrotizing fasciitis (OR, 1.01; 95% CI, 0.31–3.33). Conclusion Clindamycin reduces mortality in patients with invasive GAS disease who have necrotizing fasciitis.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Bisno AL. Streptococcus pyogenes, in Mandell GL, Bennett JE, Dolin R (eds): Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. New York, Churchill Livingstone, 1995, ed 4, pp 1786–1799.
 
2. American Public Health Association. Streptococcal diseases caused by Group A (β-hemolytic) streptococci, in Chin JE (ed): Control of Communicable Diseases Manual. Washington, DC, American Public Health Association, 2000, ed 17, pp 470–476.
 
3. Centers for Disease Control and Prevention. Summary of notifiable diseases, United States, 1998. MMWR Morb Mortal Wkly Rep 1999; 47 (53): ii-92.
 
4. Basma H, Norrby-Teglund A, Guedez Y, McGeer A, Low DE, El-Ahmedy O, et al. Risk factors in the pathogenesis of invasive Group A streptococcal infections: Role of protective humoral immunity. Infect Immun 1999; 67: 1871–1877.
 
5. Weiss K, Laverdiere M, Lovgren M, Delorme J, Poirier L, Beliveau C. Group A Streptococcus carriage among close contacts of patients with invasive infections. Am J Epidemiol 1999; 149: 863–868.
 
6. Stevens DL. Streptococcal toxic shock syndrome: Spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect Dis 1995; 1: 69–78.
 
7. Florida Bureau of Epidemiology. Streptococcal disease, invasive Group A, in Florida Morbidity Statistics, 1996. Tallahassee, Florida Department of Health, Bureau of Epidemiology, p 83.
 
8. Bernaldo de Quiros JC, Moreno S, Cercenado E, Diaz D, Berenguer J, Miralles P, et al. Group A streptococcal bacteremia: A 10-year prospective study. Medicine (Baltimore) 1997; 76: 238–248.
 
9. Francis J, Warren RE. Streptococcus pyogenes bacteraemia in Cambridge: A review of 67 episodes. Q J Med 1988; 68: 603–613.
 
10. Navarro VJ, Axelrod PI, Pinover W, Hockfield HS, Kostman JR. A comparison of Streptococcus pyogenes (Group A streptococcal) bacteremia at an urban and a suburban hospital: The importance of intravenous drug use. Arch Intern Med 1993; 153: 2679–2684.
 
11. Kaul R, McGeer A, Low DE, Green K, Schwartz B. Population-based surveillance for Group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Am J Med 1997; 103: 18–24.
 
12. Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with β-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 1999; 18: 1096–1100.
 
13. Centers for Disease Control and Prevention, Division of Bacterial and Mycotic Diseases. Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program Network, Group AStreptococcus, 1999. Available at: http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gas99.pdf. Accessed April 1, 2003.
 
14. SAS Institute, Inc. The LOGISTIC procedure, in SAS/STAT User's Guide, version 6. Cary, NC, SAS Institute, 1989, vol 2, ed 4, pp 1071–1126.
 
15. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989; 79: 340–349.
 
16. Kleinbaum DG, Kupper LL, Muller KE. Applied Regression Analysis and Other Multivariable Methods. Boston, PWS-Kent, 1988, ed 2.
 
17. Davies HD, McGeer A, Schwartz B, Green K, Cann D, Simor AE, et al. Invasive Group A streptococcal infections in Ontario, Canada. N Engl J Med 1996; 335: 547–554.
 
18. Eriksson BK, Andersson J, Holm SE, Norgren M. Epidemiological and clinical aspects of invasive Group A streptococcal infections and the streptococcal toxic shock syndrome. Clin Infect Dis 1998; 27: 1428–1436.
 
19. Zurawski CA, Bardsley M, Beall B, Elliott JA, Facklam R, Schwartz B, et al. Invasive Group A streptococcal disease in metropolitan Atlanta: A population-based assessment. Clin Infect Dis 1998; 27: 150–157.
 
20. Hoge CW, Schwartz B, Talkington DF, Breiman RF, MacNeill EM, Englender SJ. The changing epidemiology of invasive Group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome: A retrospective population-based study. JAMA 1993; 269: 384–389.
 
21. Jha AK, Shlipak MG, Hosmer W, Frances CD, Browner WS. Racial differences in mortality among men hospitalized in the Veterans Affairs health care system. JAMA 2001; 285: 297–303.
 
22. Medical Economics Staff. Physician's Desk Reference 2001. Montvale, NJ, Medical Economics Co., 2001, ed 55.
 
23. Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: Efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988; 158: 23–28.
 
24. The Working Group on Severe Streptococcal Infections. Defining the Group A streptococcal toxic shock syndrome: Rationale and consensus definition. JAMA 1993; 269: 390–391(comment).